Paul D. Rubin is a corporate partner based in the Washington, D.C. office and is the Co-Chair of the firm’s Healthcare & Life Sciences Group ...
Read Full Biography
- Due to the sensitive nature of Mr. Rubin’s confidential work counseling companies on FDA/FTC compliance matters, and handling non-public investigations, only a portion of his representative matters can be publicly disclosed.
Mergers & Acquisitions –Regulatory Due Diligence
- A leading private equity sponsor in its sale of a contract development and manufacturing organization to two private equity sponsors.
- Johnson & Johnson in its acquisition of TARIS, a biotechnology company specializing in the development of a novel drug delivery technology for the treatment of cancer.
- Allergan in its sale of Brazikumab to AstraZeneca and Zenpep to Nestle.
- Prudential Financial in its $2.35 billion acquisition of Assurance IQ, a direct-to-consumer platform that transforms the buying experience for individuals seeking personalized health and financial wellness solutions.
- Manna Pro, a manufacturer and marketer of pet care and nutrition products and a Morgan Stanley Capital Partners portfolio company, in its acquisition of Hero Pet Brands.
FDA/FTC Compliance Matters
- Numerous FDA and non-FDA regulated companies in confidential FTC investigations.
- A leading marketing company in settling advertising allegations with the FTC. new matter.
- Numerous pharmaceutical, medical device, and consumer product companies in addressing complex FDA compliance issues.
- Numerous investment banks and financial services companies in various hemp and CBD regulatory issues.
- Medical Device Innovation Consortium, in preparing a comprehensive “cybersecurity playbook” for the medical device industry.
- University of Pennsylvania Law School, J.D.
- University of Pennsylvania, Wharton School, B.S.